Literature DB >> 11711038

AMPA and GABA(B) receptor antagonists and their interaction in rats with a genetic form of absence epilepsy.

R M Kamiński1, C M Van Rijn, W A Turski, S J Czuczwar, G Van Luijtelaar.   

Abstract

The effects of combined and single administration of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, 7,8-methylenedioxy-1-(4-aminophenyl)-4-methyl-3-acetyl-4,5-dihydro-2,3-benzodiazepine (LY 300164), and of the GABA(B) receptor antagonist gamma-aminopropyl-n-butyl-phosphinic acid (CGP 36742), on spontaneously occurring spike-wave discharges were investigated in WAG/Rij rats. LY 300164 had minor effects; only the highest dose (16 mg/kg) reduced the number of spike-wave discharges in a short time window. CGP 36742 was more effective as it significantly reduced the number of spike-wave discharges and shortened their duration at the doses of 25 and 100 mg/kg. The ED(50) values for the inhibition of spike-wave discharges by LY 300164 and CGP 36742 in a time window 30-60 min after injection were 15.5 and 16.6 mg/kg, respectively. The ED(50) of CGP 36742 was reduced to 8.0 mg/kg when this antagonist was administered in combination with LY 300164 (6 mg/kg). The interaction between the two antagonists appeared to be additive according to isobolographic analysis. Importantly, CGP 36742 and LY 300164 administered either alone or in combination had no apparent effects on behavior. These results may provide information for a rational approach to polytherapy for the treatment of generalized absence epilepsy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711038     DOI: 10.1016/s0014-2999(01)01393-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Molecular targets for antiepileptic drug development.

Authors:  Brian S Meldrum; Michael A Rogawski
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

2.  Revisiting AMPA receptors as an antiepileptic drug target.

Authors:  Michael A Rogawski
Journal:  Epilepsy Curr       Date:  2011-03       Impact factor: 7.500

Review 3.  Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist.

Authors:  M A Rogawski; T Hanada
Journal:  Acta Neurol Scand Suppl       Date:  2013

4.  Neurochemical and behavioral features in genetic absence epilepsy and in acutely induced absence seizures.

Authors:  A S Bazyan; G van Luijtelaar
Journal:  ISRN Neurol       Date:  2013-05-07

Review 5.  Perampanel: What is its Place in the Management of Partial Onset Epilepsy?

Authors:  David R M Ledingham; Philip N Patsalos
Journal:  Neurol Ther       Date:  2013-08-30

6.  Synaptic Changes in AMPA Receptor Subunit Expression in Cortical Parvalbumin Interneurons in the Stargazer Model of Absence Epilepsy.

Authors:  Nadia K Adotevi; Beulah Leitch
Journal:  Front Mol Neurosci       Date:  2017-12-22       Impact factor: 5.639

Review 7.  Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy.

Authors:  Roberta Celli; Francesco Fornai
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.